BRPI0616703A2 - forma de dosagem farmacêutica - Google Patents

forma de dosagem farmacêutica

Info

Publication number
BRPI0616703A2
BRPI0616703A2 BRPI0616703A BRPI0616703A BRPI0616703A2 BR PI0616703 A2 BRPI0616703 A2 BR PI0616703A2 BR PI0616703 A BRPI0616703 A BR PI0616703A BR PI0616703 A BRPI0616703 A BR PI0616703A BR PI0616703 A2 BRPI0616703 A2 BR PI0616703A2
Authority
BR
Brazil
Prior art keywords
dosage form
pharmaceutical dosage
pharmaceutical
dosage
Prior art date
Application number
BRPI0616703A
Other languages
English (en)
Inventor
Ann F Hsu
Chien-Hsuan Han
Larry Hsu
Original Assignee
Impax Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impax Laboratories Inc filed Critical Impax Laboratories Inc
Publication of BRPI0616703A2 publication Critical patent/BRPI0616703A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0616703A 2005-09-30 2006-09-20 forma de dosagem farmacêutica BRPI0616703A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/239,249 US8007827B2 (en) 2004-04-02 2005-09-30 Pharmaceutical dosage forms having immediate release and/or controlled release properties
PCT/US2006/036694 WO2007040997A2 (en) 2005-09-30 2006-09-20 Pharmaceutical dosage forms having immediate release and/or controlled release properties

Publications (1)

Publication Number Publication Date
BRPI0616703A2 true BRPI0616703A2 (pt) 2016-09-06

Family

ID=37906654

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616703A BRPI0616703A2 (pt) 2005-09-30 2006-09-20 forma de dosagem farmacêutica

Country Status (12)

Country Link
US (1) US8007827B2 (pt)
EP (1) EP1940361B1 (pt)
JP (1) JP5366549B2 (pt)
KR (1) KR20080059409A (pt)
CN (1) CN101312716A (pt)
AU (1) AU2006297477B2 (pt)
BR (1) BRPI0616703A2 (pt)
CA (1) CA2625481C (pt)
ES (1) ES2561585T3 (pt)
TR (1) TR200804209T1 (pt)
TW (1) TW200735899A (pt)
WO (1) WO2007040997A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
HUE029173T2 (hu) 2006-04-26 2017-02-28 Alphapharm Pty Ltd Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot
GB2443738A (en) * 2006-11-09 2008-05-14 Proprius Pharmaceuticals Inc A sustained release methotrexate composition and methods of use thereof
US20080268045A1 (en) * 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
CN101910113A (zh) 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
PE20170306A1 (es) 2010-06-16 2017-05-06 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
US8685947B2 (en) * 2010-08-25 2014-04-01 Brown University Compositions and methods for loop diuretics with consistent bioavailability
CN102416170B (zh) * 2011-11-07 2013-08-07 重庆申高生化制药有限公司 多酶片的生产工艺
WO2013110975A1 (es) * 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
US20140106026A1 (en) * 2012-10-16 2014-04-17 Raphael Wald Article and method for treating, preventing and ameliorating alcohol-induced wernicke-korsakoff syndrome
JP2016516717A (ja) 2013-03-15 2016-06-09 シーダーズ−サイナイ メディカル センター メタン細菌に起因または関連する疾患および状態を診断、選択、および処置する方法
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
KR101561345B1 (ko) * 2013-10-17 2015-10-16 대원제약주식회사 제어방출되는 프로피온산 계열의 약제학적 조성물
KR102425303B1 (ko) 2014-08-13 2022-07-25 세다르스-신나이 메디칼 센터 항-메탄생성 조성물 및 그것의 용도
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
EP3258914A1 (en) 2015-02-20 2017-12-27 Osmotica Kereskedelmi ES Szolgaltato KFT Controlled release oral dosage form of gaba receptor agonist
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
KR20160105662A (ko) * 2015-02-27 2016-09-07 대원제약주식회사 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
CA3013795A1 (en) * 2016-02-17 2017-08-24 Corr-Jensen Inc. Time release vitamins and minerals in edible oils
CN105748444B (zh) * 2016-03-30 2018-08-31 济南康和医药科技有限公司 一种双相释放的头孢妥仑匹酯制剂及其制备方法
SG11201807402PA (en) * 2016-03-31 2018-09-27 Vhsquared Ltd Compositions
CN108822816A (zh) * 2018-06-25 2018-11-16 中国石油集团渤海钻探工程有限公司 一种疏松砂岩用可酸溶凝胶堵漏剂及其制备方法
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
CN113018273B (zh) * 2019-12-25 2024-08-09 上海宣泰医药科技股份有限公司 一种固体制剂及其制备方法和用途
EP3854385A1 (en) 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
HUE067496T2 (hu) 2020-12-08 2024-10-28 Ruminant Biotech Corp Ltd Az állatoknak szánt anyagok bejuttatására szolgáló eszközök és módszerek fejlesztése
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
WO2022245650A1 (en) * 2021-05-19 2022-11-24 Alberto Paz Orally administered compositions for cancer treatment
CN117137877A (zh) * 2023-10-09 2023-12-01 重庆士立德医药科技有限公司 一种巴氯芬缓释片及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122039C (pt) * 1960-10-20
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
US4764380A (en) 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4780463A (en) * 1984-12-26 1988-10-25 Analgesic Associates Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9308430D0 (en) 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
JPH072650A (ja) * 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
HUT77530A (hu) 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
EP0807433A4 (en) 1994-12-27 2005-12-28 Akzo Nobel Nv PREPARING WITH DELAYED RELEASE
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use
EP0951278A2 (en) 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
US7119189B2 (en) * 1997-03-19 2006-10-10 Novartis Ag Metabotropic GABA [B] receptors, receptor-specific ligands and their uses
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
WO2000024423A1 (en) 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Sustained-release particles
MXPA01004381A (es) 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6350769B1 (en) 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2001055322A (ja) * 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd パルス放出型製剤
FR2798289B1 (fr) 1999-09-15 2004-12-31 Cll Pharma Formes galeniques a delitement rapide en bouche et leur procede de preparation
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
CA2430298A1 (en) 2000-11-30 2002-06-06 Banavara Lakshman Mylari Combination of gaba agonists and sorbitol dehydrogenase inhibitors
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
JP3934383B2 (ja) * 2001-10-11 2007-06-20 アルフレッサファーマ株式会社 経口投与用製剤
US6781560B2 (en) 2002-01-30 2004-08-24 Harris Corporation Phased array antenna including archimedean spiral element array and related methods
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
EP1589951B1 (en) * 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2007201808B8 (en) 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity
AU2007261098A1 (en) 2006-06-19 2007-12-27 Mcneil-Ppc, Inc. Enteric coated particles containing an active ingredient

Also Published As

Publication number Publication date
JP5366549B2 (ja) 2013-12-11
TR200804209T1 (tr) 2008-08-21
EP1940361B1 (en) 2015-11-04
CN101312716A (zh) 2008-11-26
CA2625481C (en) 2012-01-03
ES2561585T3 (es) 2016-02-29
US8007827B2 (en) 2011-08-30
KR20080059409A (ko) 2008-06-27
JP2009510065A (ja) 2009-03-12
WO2007040997A3 (en) 2007-09-27
CA2625481A1 (en) 2007-04-12
US20060057197A1 (en) 2006-03-16
WO2007040997A2 (en) 2007-04-12
TW200735899A (en) 2007-10-01
AU2006297477B2 (en) 2011-02-10
EP1940361A4 (en) 2011-03-02
EP1940361A2 (en) 2008-07-09
AU2006297477A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
BRPI0616703A2 (pt) forma de dosagem farmacêutica
DK2343071T3 (da) Farmaceutiske doseringsformer
DK2041139T3 (da) Farmaceutiske forbindelser
IL251539A0 (en) Single pharmaceutical dosage form
DK1986650T3 (da) Manipulationssikre doserignsformer
EP1992348A4 (en) PHARMACEUTICAL COMBINATION
DK1907037T4 (da) Lægemiddeldispenser
RU2398586C3 (ru) Фармацевтическая композиция
BRPI0715712A2 (pt) Composição farmacêutica
NO20075628L (no) Farmasøytiske formuleringer
BRPI0810646A2 (pt) " compostos farmacêuticos ".
BRPI0719393A2 (pt) Composição farmacêutica
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
IL184858A (en) Alcohol resistant dosage forms
DK1957073T3 (da) Lægemiddel
ATE453384T1 (de) Neue dosierformulierung
DE602006013636D1 (de) Dosiszähler
BRPI0812964A2 (pt) Forma de dosagem farmacêutica oral sólida
BRPI0807882A2 (pt) Forma de dosagem
SI1942967T1 (sl) Postopek za odmerjanje zdravil
ZA200803152B (en) Oramucosal pharmaceutical dosage form
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20080046461/RJ DE 28/03/2008.

B11M Dismissal: decision cancelled

Free format text: O DESPACHO 11.6.1 DA RPI 2195 DE 29/01/2013 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]